Want to get up to scratch on the latest 3D Cancer Models? Download our whitepaper! 👉 Swipe through to see what you'll learn, including six applications of our 3D tumor modeling capabilities. Explore these applications and other exciting topics in the whitepaper and discover how MIMETAS can help you close the translational gap in cancer drug discovery: https://lnkd.in/eS9r_6-h #CancerResearch #DrugDiscovery #Oncology #OncologyResearch #CancerDrugDiscovery
MIMETAS’ Post
More Relevant Posts
-
Author Correction: Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives 🔬 #ClinicalOncology #Oncology #Cancer
-
Excited to share my latest conference abstract publication: "Irinotecan and S-1 Combination in Non-Small Cell Lung Cancer: Efficacy and Toxicity - A Systematic Review and Meta-Analysis." Explore the findings and insights here: https://lnkd.in/de4KbGzc. #LungCancerResearch #MedicalResearch #Oncology #MetaAnalysis
-
-
February is National Cancer Prevention Month. For those with a brain cancer diagnosis, whether a primary tumor or a tumor that metastasized to the brain—see if GammaTile might be a treatment option for you, learn more about GammaTile® : https://shorturl.at/FKNWZ #cancerawarenessmonth #braincancer #braintumor #oncology #medtech #GammaTile
-
RPh, CPh, PhD — Oncology Infusion Pharmacy Services Manager at Moffitt Cancer Center — Do not judge each day by the harvest you reap, but by the seeds that you plant.
Signatera is a blood test that can identify molecular residual disease, or recurrent cancer, sooner than existing methods, by detecting the presence of ctDNA. Signatera is a personalized, tumor-informed test optimized to detect ctDNA with high sensitivity and specificity. https://lnkd.in/eSKGUrBq #Cancer #Oncology #CirculatingTumorDNA #ctDNA #Signatera
-
Have a look on ongoing developments for pre-clinical research. #CancerResearch #Oncology #PDX #PDXO #CRO #PreclinicalModels #Invitro #Invivo
[From PDX… to PDXO 📋🔎] #PDX models are instrumental in cancer research, allowing for the study of tumor behavior in a living organism. However, the emergence of #PDX #Organoid models has revolutionized this approach by enabling more precise and scalable in vitro studies while maintaining the complexity and heterogeneity of human tumors. Check out the infographic below to explore these advancements in detail and understand how PDXO models are paving the way for the next generation of cancer therapies. More information about our PDXO models : https://lnkd.in/ewQn_AXE #CancerResearch #Oncology #PDX #PDXO #CRO #PreclinicalModels #Invitro #Invivo #Organoid
-
Douglas Flora, MD, LSSBB, FACCC Announces Latest Release of AI in Precision Oncology Douglas Flora shares that the latest release of AI in Precision Oncology is now available. This edition explores the role of artificial intelligence in advancing cancer screening, with detailed discussions on various strategies and tumor types. Highlighted in this release is an article by Maysaa El Zoghbi and Seth Gross, providing valuable insights into recent AI advancements in oncology. https://lnkd.in/ef2QhT34 #AIinOncology #CancerScreening #Cancer #Oncology #OncoDaily
-
-
A telomere-targeting drug depletes cancer initiating cells and promotes anti-tumor immunity in small cell lung cancer. An article was recently published in an important journal, highlighting the potential breakthroughs of THIO in lung cancer. Read here: https://lnkd.in/dJC-v8pH #Oncology #OncNews #Science
-
-
Great news! Another targeted therapy approved for patients with early-stage/locally advanced NSCLC after surgical resection 🫁 How do we “select” the patients who will derive benefit? 🧪This highlights the important role of biomarker testing to #personalize therapy even in early-stage setting. Patients with ALK-positive tumors of at least 4 cm or lymph node positivity benefited from therapy in the study What was the study? 📈Phase III ALINA trial demonstrated that adjuvant alectinib reduced risk for lung cancer recurrence by 76% vs. chemotherapy after surgical resection Congratulations to the patients and investigators! 🙌🏻 #precisionmedicine #NSCLCsm
BREAKING: The FDA has approved alectinib (Alecensa) for use as adjuvant treatment following tumor resection in patients with ALK-positive non–small cell lung cancer whose tumors are at least 4 cm or node positive. #lcsm #oncology https://lnkd.in/eiqWgjaq
-
-
EACR's workshop on AI in multi-country oncology imaging European Association for Cancer Research (EACR) #Cancer #ClinicalPerspective #EACR #OncoDaily #Oncology
EACR's workshop on AI in multi-country oncology imaging - OncoDaily
oncodaily.com
-
🔍 Q2 2024 Update: Uncover the Most Discussed Breast Cancer Trials by top oncologists on X (formerly Twitter). With LARVOL, get the latest insights driving the conversation in cancer research. 💡🩺 #LARVOL #BreastCancer #ClinicalTrials #Oncology #CancerResearch #OncologyUpdates #CancerTreatment #CancerCare
-
